Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 8:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1033–1056 of 3,561 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Non-small Cell Lung Cancer (NSCLC) Clear all
Completed Phase 2 Interventional Results available

Single Agent Alimta in Poor Performance Status in Non-small Cell Lung Cancer

NCT00508144
View directory record Official record
Conditions
Lung Cancer
Interventions
Alimta
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 13, 2017 · Synced Oct 18, 2026, 8:06 AM EDT
Not listed Phase 2 Interventional

Oral NRX 194204 Study in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

NCT00964132
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
NRX194204
Drug
Lead sponsor
NuRx Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
6
States / cities
Fountain Valley, California • La Jolla, California • Los Angeles, California + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2009 · Synced Oct 18, 2026, 8:06 AM EDT
Active, not recruiting Phase 1 Interventional

Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer

NCT04612751
View directory record Official record
Conditions
Advanced or Metastatic NSCLC
Interventions
Datopotamab deruxtecan, Durvalumab, Carboplatin, AZD2936, MEDI5752, AZD7789
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
10
States / cities
La Jolla, California • Santa Ana, California • St Louis, Missouri + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 18, 2026, 8:06 AM EDT
Recruiting No phase listed Observational

LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer Cachexia

NCT06073431
View directory record Official record
Conditions
Advanced Colorectal Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Pancreatic Adenocarcinoma, Stage IV Colorectal Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Colorectal Carcinoma, Unresectable Lung Non-Small Cell Carcinoma, Unresectable Pancreatic Adenocarcinoma
Interventions
Biospecimen Collection, Computed Tomography, Electronic Health Record Review, Medical Device Usage and Evaluation, Physical Performance Testing, Positron Emission Tomography, Survey Administration
Procedure · Other
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
225
States / cities
Fort Smith, Arkansas • Aurora, Colorado • Boulder, Colorado + 160 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2026 · Synced Oct 18, 2026, 8:06 AM EDT
Active, not recruiting Phase 3 Interventional

Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer

NCT05132075
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
JDQ443, docetaxel
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Renton, Washington
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 18, 2026, 8:06 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)

NCT03829319
View directory record Official record
Conditions
Nonsquamous Non-small Cell Lung Cancer
Interventions
Pembrolizumab, Carboplatin, Cisplatin, Pemetrexed, Lenvatinib, Placebo matching lenvatinib
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
761 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
17
States / cities
Mountain View, California • New Haven, Connecticut • Fort Lauderdale, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 18, 2026, 8:06 AM EDT
Completed Phase 1 Interventional

Chemotherapy Plus Trastuzumab in Treating Patients With Breast Cancer

NCT00014430
View directory record Official record
Conditions
Breast Cancer
Interventions
trastuzumab, vinorelbine ditartrate
Biological · Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Mar 14, 2013 · Synced Oct 18, 2026, 8:06 AM EDT
Not listed Phase 1Phase 2 Interventional

Bortezomib (Velcade) + Pemetrexed (Alimta) in Advanced NSCLC

NCT00516100
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
bortezomib
Drug
Lead sponsor
Aptium Oncology Research Network
Network
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
4
States / cities
Los Angeles, California • Palm Springs, California • San Francisco, California + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2010 · Synced Oct 18, 2026, 8:06 AM EDT
Completed Phase 2 Interventional Results available

Study of Pralatrexate vs. Erlotinib for Non-Small Cell Lung Cancer After at Least 1 Prior Platinum-based Treatment

NCT00606502
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Pralatrexate, Erlotinib, Vitamin B12, Folic Acid
Drug · Dietary Supplement
Lead sponsor
Spectrum Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
15
States / cities
Bakersfield, California • San Diego, California • Port Saint Lucie, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2021 · Synced Oct 18, 2026, 8:06 AM EDT
Withdrawn Phase 1 Interventional

Radiation Therapy and Ammonium Tetrathiomolybdate in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer

NCT00560495
View directory record Official record
Conditions
Lung Cancer
Interventions
ammonium tetrathiomolybdate, immunoenzyme technique, laboratory biomarker analysis, Tc 99m sestamibi, radiation therapy
Drug · Other · Radiation
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 3, 2022 · Synced Oct 18, 2026, 8:06 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Biomarkers in the Nose, Throat, and Lung Tissue of Smokers and Non-Smokers

NCT00897364
View directory record Official record
Conditions
Lung Cancer, Precancerous Condition
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
45 Years and older
Enrollment
112 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2009
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 15, 2020 · Synced Oct 18, 2026, 8:06 AM EDT
Completed Phase 1 Interventional

CPT-11/Cisplatin and Celecoxib With Radiation Therapy for Patients With Unresectable Non-Small Cell Lung Cancer (NSCLC)

NCT00346801
View directory record Official record
Conditions
Lung Cancer
Interventions
Celecoxib, Cisplatin, CPT-11, Concurrent Thoracic Radiation Therapy
Drug · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 22, 2012 · Synced Oct 18, 2026, 8:06 AM EDT
Terminated Not applicable Interventional

Thermal Ablation Combined With External Beam Radiation Therapy for Patients With Inoperable Non-Small Cell Lung Cancer > 3.5 cm in Size

NCT01028612
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
thermal ablation with external beam radiation
Radiation
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 1, 2018 · Synced Oct 18, 2026, 8:06 AM EDT
Terminated Phase 2 Interventional Results available

A Study of LY3023414 and Necitumumab in Squamous Lung Cancer

NCT02443337
View directory record Official record
Conditions
Non-small Cell Lung Cancer Metastatic
Interventions
LY3023414, Necitumumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
14
States / cities
Mobile, Alabama • Chandler, Arizona • Englewood, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2020 · Synced Oct 18, 2026, 8:06 AM EDT
Completed Phase 1Phase 2 Interventional

Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors

NCT04902872
View directory record Official record
Conditions
Solid Tumor, Adult, Epithelial Ovarian Cancer, Small Cell Lung Carcinoma, Breast Cancer, Colorectal Cancer, Pancreas Cancer, Appendix Cancer, Non-small Cell Lung Cancer, Gastric Cancer, Esophagus Cancer, Urothelial Carcinoma, Sarcoma
Interventions
CBX-12
Drug
Lead sponsor
Cybrexa Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
4
States / cities
New Haven, Connecticut • Austin, Texas • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 18, 2026, 8:06 AM EDT
Completed Phase 2 Interventional Results available

Erlotinib vs. Standard Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) and Eastern Cooperative Oncology Group (ECOG)Performance Status (PS) 2

NCT00085839
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Tarceva (Trademark) (erlotinib HCl, OSI-774), Combination carboplatin and paclitaxel
Drug
Lead sponsor
OSI Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
19
States / cities
Greenbrae, California • San Diego, California • Fort Lauderdale, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2012 · Synced Oct 18, 2026, 8:06 AM EDT
Completed Phase 3 Interventional

Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer

NCT00347412
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Paclitaxel, NOV-002, Carboplatin
Drug
Lead sponsor
Cellectar Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
903 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
12
States / cities
Muscle Shoals, Alabama • San Diego, California • Chicago, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2022 · Synced Oct 18, 2026, 8:06 AM EDT
Completed Phase 2 Interventional

FR901228 in Treating Patients With Refractory or Progressive Small Cell Lung Cancer or Non-small Cell Lung Cancer

NCT00020202
View directory record Official record
Conditions
Extensive Stage Small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer, Recurrent Small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer
Interventions
FR901228
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Timeline
2000 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2024 · Synced Oct 18, 2026, 8:06 AM EDT
Completed Not applicable Interventional

Proton Therapy for Stage I Non-Small Cell Lung Cancer (LU03)

NCT00875901
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Peripherally located lung tumor, Centrally located lung tumor
Radiation
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2022
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 24, 2022 · Synced Oct 18, 2026, 8:06 AM EDT
Active, not recruiting Phase 3 Interventional

Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)

NCT06726265
View directory record Official record
Conditions
Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
Interventions
eftilagimod alfa, carboplatin plus paclitaxel, cisplatin or carboplatin + pemetrexed, pembrolizumab (KEYTRUDA®), Placebo
Biological · Drug · Other
Lead sponsor
Immutep S.A.S.
Industry
Eligibility
18 Years and older
Enrollment
756 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
3
States / cities
Louisville, Kentucky • Albuquerque, New Mexico • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Oct 18, 2026, 8:06 AM EDT
Completed No phase listed Observational

Identification of Genes Associated With Cancer in Patients and Siblings Who Have Cancer

NCT00003329
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer
Interventions
gene mapping
Genetic
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
0 Years to 120 Years
Enrollment
4,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
32
States / cities
Rancho Mirage, California • Fort Collins, Colorado • Boca Raton, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2023 · Synced Oct 18, 2026, 8:06 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Osimertinib and Bevacizumab as Treatment for EGFR-mutant Lung Cancers

NCT02803203
View directory record Official record
Conditions
Non-small Cell Lung Cancer, EGFR-mutant Lung Cancers
Interventions
osimertinib, Bevacizumab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
19 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2023 · Synced Oct 18, 2026, 8:06 AM EDT
Completed Phase 2 Interventional

Alanosine in Treating Patients With Cancer

NCT00062283
View directory record Official record
Conditions
Lung Cancer, Malignant Mesothelioma, Pancreatic Cancer, Sarcoma
Interventions
L-alanosine
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
13 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
12
States / cities
Birmingham, Alabama • Tucson, Arizona • La Verne, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2013 · Synced Oct 18, 2026, 8:06 AM EDT
Completed Early Phase 1 Interventional

Genomically Guided Radiation Dose Personalization in Locally Advanced NSCLC

NCT05873439
View directory record Official record
Conditions
Nonsmall Cell Lung Cancer, Nonsmall Cell Lung Cancer, Stage II, Nonsmall Cell Lung Cancer Stage III, Unresectable Non-Small Cell Lung Carcinoma
Interventions
Genomically Guided Radiation Therapy (RT)
Radiation
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 18, 2026, 8:06 AM EDT